Krystal Biotech (KRYS) Other Non-Current Assets (2018 - 2026)
Krystal Biotech recorded quarterly Other Non-Current Assets of $300000.0 in Q1 2026, up 4.53% quarter-over-quarter from $287000.0 in Q4 2025, and up 37.61% year-over-year from $218000.0 in Q1 2025.
Krystal Biotech's Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $300000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 37.61% year-over-year to $300000.0; the TTM figure through Mar 2026 stood at $300000.0 (up 37.61% YoY), while the FY2025 annual figure was $287000.0, up 24.24% from the prior year.
- Other Non-Current Assets came in at $300000.0 for Q1 2026 at Krystal Biotech, up from $287000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $402000.0 in Q1 2023 to a low of $126000.0 in Q2 2024.
- A 5-year average of $245352.9 and a median of $231000.0 in 2024 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 337.84% in 2022 and sank 55.79% in 2024, its largest moves.
- Krystal Biotech's Other Non-Current Assets stood at $324000.0 in 2022, then decreased by 18.83% to $263000.0 in 2023, then declined by 12.17% to $231000.0 in 2024, then advanced by 24.24% to $287000.0 in 2025, then grew by 4.53% to $300000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $300000.0, $287000.0, and $333000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Krystal Biotech | 9.05 Bn | 8.23 Bn | 110.03 Mn | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 287,000.00 |
| Sep 30, 2025 | 333,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Mar 31, 2025 | 218,000.00 |
| Dec 31, 2024 | 231,000.00 |
| Sep 30, 2024 | 203,000.00 |
| Jun 30, 2024 | 126,000.00 |
| Mar 31, 2024 | 196,000.00 |
| Dec 31, 2023 | 263,000.00 |
| Sep 30, 2023 | 285,000.00 |
| Jun 30, 2023 | 285,000.00 |
| Mar 31, 2023 | 402,000.00 |
| Dec 31, 2022 | 324,000.00 |
| Sep 30, 2022 | 205,000.00 |
| Jun 30, 2022 | 159,000.00 |
| Mar 31, 2022 | 157,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Sep 30, 2021 | 62,000.00 |
| Jun 30, 2021 | 110,000.00 |
| Mar 31, 2021 | 109,000.00 |
| Dec 31, 2020 | 1.61 Mn |
| Sep 30, 2020 | 1.41 Mn |
| Mar 31, 2020 | 1.51 Mn |
| Dec 31, 2019 | 1.46 Mn |
| Sep 30, 2019 | 138,000.00 |
| Jun 30, 2019 | 86,000.00 |
| Mar 31, 2019 | 455,000.00 |
| Dec 31, 2018 | 452,000.00 |
| Jun 30, 2018 | 64,000.00 |